BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32157655)

  • 1. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
    Kara M; Tokat F; Pamir MN; Danyeli AE
    Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
    Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
    Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
    García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p16
    Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
    J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
    Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
    Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
    Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
    Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
    Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
    J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
    Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
    Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
    Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
    Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
    Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors.
    Portovedo S; Gaido N; de Almeida Nunes B; Nascimento AG; Rocha A; Magalhães M; Nascimento GC; Pires de Carvalho D; Soares P; Takiya C; Faria MDS; Miranda-Alves L
    Mol Cell Endocrinol; 2019 Jun; 490():80-87. PubMed ID: 30999005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.